DXA interval change exceeding least significant change (LSC)
An interval decrease in DXA bone mineral density (BMD) that exceeds the least significant change (LSC) indicates a statistically significant change beyond DXA test-retest measurement error, consistent with true bone loss at the measured site. [1], [2]
Least significant change concept
LSC represents the magnitude of DXA BMD change that must be equaled or exceeded to be considered statistically significant at the predefined confidence level. [1], [2] LSC is derived from the facility and instrument precision for the specific measurement site and scanner. [2], [3]
Clinical meaning of a 5.2% interval decrease exceeding LSC
A 5.2% interval decrease that exceeds the LSC is reported as “clinically significant” or “statistically significant” decline in BMD, rather than random variation from measurement precision. [1], [2] This finding supports biological bone loss over the interval between scans. [1], [2]
Interpretation constraints
This interpretation assumes that the comparison is valid, including measurement on the same DXA system with appropriate positioning and consistent anatomical site selection for monitoring. [3] When clinical history is incompatible with the magnitude or timing of change (for example, apparent dramatic change over a short period), reassessment of technical factors and scanning conditions is recommended before concluding true change. [3]
Sources of LSC determination used in serial monitoring
Facility-specific LSC should be calculated using precision assessment for the DXA instrument and measurement site rather than relying on manufacturer values alone. [2], [3]
Practical reporting implication for serial DXA monitoring
The interval decrease that exceeds LSC should be interpreted as a true decline in BMD for purposes of monitoring response to therapy or progression of bone loss, rather than as an insignificant change. [1], [2]
Key follow-up actions when significant decline is present
Clinical correlation should be performed with adherence to therapy and evaluation for secondary causes of bone loss when a significant decline in BMD is observed. [3]